Figure 4. TP53 mutations predictive for trastuzumab benefit.

Interactions between TP53 mutations and trastuzumab (A), and between p53 protein expression and trastuzumab (B) are shown. Trastuzumab (T) treated patients with TP53 mutations (A) or p53 positive protein expression by IHC (B) fared best; patients with the same TP53 tumor properties, who were not treated with trastuzumab, fared worst.